Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 4,39€(+57,35%). Der Median liegt bei 4,39€(+57,35%).
Kaufen | 7 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -7 / 13 |
News
Savara: Make-It-Or-Break-It Molbreevi BLA Filing
Savara, Inc. focuses exclusively on developing its sole therapeutic product, MOLBREEVI. Its investment thesis highlights the potential of MOLBREEVI to address unmet medical needs in autoimmune pulmonary alveolar proteinosis (aPAP). Rating justification: Strong clinical data, multiple FDA designations and a clear path to regulatory approval make Savara a compelling investment opportunity.» Mehr auf seekingalpha.com
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 107,000 shares of the Company's common stock and restri.» Mehr auf businesswire.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-1.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 261,40k | - |
Bruttoeinkommen | 130,70k | 318,91% |
Nettoeinkommen | −27,91 Mio | 91,66% |
EBITDA | −29,93 Mio | 88,36% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 481,51 Mio€ |
Anzahl Aktien | 172,63 Mio |
52 Wochen-Hoch/Tief | 4,66€ - 1,98€ |
Dividenden | Nein |
Beta | 0,52 |
KGV (PE Ratio) | −6,57 |
KGWV (PEG Ratio) | −0,07 |
KBV (PB Ratio) | 3,68 |
KUV (PS Ratio) | 2.018,28 |
Unternehmensprofil
Savara Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf seltene Atemwegserkrankungen konzentriert. Sein führender Produktkandidat ist Molgramostim, ein inhalativer Granulozyten-Makrophagen-Kolonie-stimulierender Faktor, der sich in der Phase III der Entwicklung zur Behandlung der autoimmunen pulmonalen alveolären Proteinose befindet. Der Hauptsitz des Unternehmens befindet sich in Austin, Texas.
Name | Savara Inc |
CEO | Matthew Pauls J.D., M.B.A. |
Sitz | Austin, tx USA |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 59 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | SVRA |
Frankfurt | YB4P.F |
Düsseldorf | YB4P.DU |
München | YB4P.MU |
Assets entdecken
Shareholder von Savara Inc investieren auch in folgende Assets